enGene Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $110.18M
- P/E (TTM)
- 0.7
- Dividend yield
- 0.00%
Earnings
Next report expected Dec 21, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Jul 31, 2026 | Sep 8, 2026 | Before market open | – | $-0.47 | – |
| Q2 FY2026 Ended Apr 30, 2026 | Jun 15, 2026 | Before market open | – | $-0.43 | – |
| Q1 FY2026 Ended Jan 31, 2026 | Mar 9, 2026 | Before market open | – | $0.44 | – |
| Q4 FY2025 Ended Oct 31, 2025 | Dec 22, 2025 | During market hours | – | – | – |
| Q3 FY2025 Ended Jul 31, 2025 | Sep 11, 2025 | During market hours | – | $0.57 | – |
| Q2 FY2025 Ended Apr 30, 2025 | Jun 12, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Jan 31, 2025 | Mar 10, 2025 | During market hours | – | $-0.48 | – |
| Q4 FY2024 Ended Oct 31, 2024 | Dec 19, 2024 | During market hours | – | – | – |
| Q3 FY2024 Ended Jul 31, 2024 | Sep 10, 2024 | During market hours | – | $0.32 | – |
| Q2 FY2024 Ended Apr 30, 2024 | Jun 14, 2024 | Before market open | – | $0.38 | – |
| Q1 FY2024 Ended Jan 31, 2024 | Mar 11, 2024 | During market hours | – | $0.46 | – |
Press releases
Announcements enGene Therapeutics filed with the SEC
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Non-Viral Genetic Medicine Virtual KOL Event: Emerging NMIBC Market Insights August 11, 2026
Other events · EX-99.1 to Form 8-K
Corporate Presentation Non-Viral Genetic Medicine
Regulation FD disclosure · EX-99.1 to Form 8-K
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LEGEND Interim Data Update May 7, 2026
Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
enGene Announces Name Change to enGene Therapeutics Inc.
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
Regulation FD disclosure · EX-99.1 to Form 8-K
enGene Reports Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
LEGEND Data Update November 11, 2025
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
enGene Announces Board and Leadership Appointments to Support Commercial Readiness
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
enGene Announces the Resignation of its Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
enGene Announces $60 Million Private Placement Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Presentation October 2024 Exhibit 99.2
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Non-Viral Genetic Medicine Preliminary Data from LEGEND Pivotal Cohort September 26, 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Non-Viral Genetic Medicine Corporate Presentation September 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
enGene: moving genetic medicines into the mainstream
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
Results of operations · EX-99.1 to Form 8-K
enGene Announces Oversubscribed $200 Million Private Placement Financing
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
enGene Announces Leadership Succession Plan
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
“believe”, “continue”, “could”, “estimate”, “expect”, “intends”, “may”, “might”, “plan”, “possible”, “project”,
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
enGene Reports Full Year 2023 Financial Results and Recent Operational Progress
Results of operations · EX-99.1 to Form 8-K
enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K